Abstract:Glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG) are currently incurable cancers. Systemic chemotherapy shows limited efficacy because of the intact blood-brain barrier. Convection-enhanced delivery (CED) offers promise by concentrating high doses of chemotherapeutics directly within these tumors. However, drugs administered via CED often face challenges in confirming precise target delivery and are quickly cleared by increased interstitial fluid flow and drug efflux transporters. This highlights the urgent need for innovative drugs that demonstrate target specificity and prolonged retention capabilities. Intrinsically disordered polypeptides (IDPs), derived from tropoelastin, self-assemble into water-insoluble structures with extended retention properties triggered by body temperature. IL13Rα2, differentially amplified in U87MG GBM and SF8628 DIPG cells, serves as a target for therapeutic intervention. An IL13Rα2-targeting IDP (XM161) was developed by incorporating IL13Rα2 binding sequences into the IDP domains. XM161 demonstrated high selectivity in binding to IL13Rα2, with Kd values of 1,786 nM for IL13Rα1 and 12.8 nM for IL13Rα2. Conjugation of XM161 with SN38, a potent topoisomerase I inhibitor, resulted in XM161-SN38, which remained in a dissolved state up to 50°C but formed insoluble aggregates above 27°C in the presence of cerebrospinal fluid. XM161-SN38 exhibited strong cytotoxicity against U87MG and SF8628 cells, with IC50 values of 14.2 nM and 0.48 nM, respectively. Importantly, XM161-SN38 demonstrated efficacy in overcoming Temozolomide resistance in T98G GBM cells, with IC50 values of 3.35 nM compared to 10.87 nM for unconjugated SN38. In orthotopic xenograft models established in BALB/cSlc-nu/nu male mice using U87MG-Luc2 cells, three doses (3 x 0.95 μg SN38 equivalents) of XM161-SN38 delivered via CED were well tolerated and significantly extended median survival to over 65 days, providing a notable survival benefit compared to untreated controls (42 days) and Topotecan-treated group (42.5 days). These findings validate the feasibility and therapeutic potential of XM161-SN38 for GBM treatment. Ongoing studies are underway to investigate the safety and pharmacokinetics of XM161-SN38 in tumor-naive mouse brains.

An MSN-PEG-IP Drug Delivery System and IL13Rα2 As Targeted Therapy for Glioma.

Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma

Tumor cell targeted delivery by specific peptide-modified mesoporous silica nanoparticles

Ddel-02. Preclinical Efficacy Of Il13Rα2-Targeting Polypeptide-Drug Conjugate (Self-Depottm Oncopdc) In Glioblastoma And Diffuse Intrinsic Pontine Glioma

Glioma Targeting and Anti-Glioma Effect of Interleukin 13 Peptide and RGD Peptide Dual Functionalized Nanoparticles.

Glioma-homing Peptide with a Cell-Penetrating Effect for Targeting Delivery with Enhanced Glioma Localization, Penetration and Suppression of Glioma Growth.

Brain-targeting biomimetic nanoparticles for codelivery of celastrol and LY2157299 for reversing glioma immunosuppression

Improved Anti-Glioblastoma Efficacy by IL-13Rα2 Mediated Copolymer Nanoparticles Loaded with Paclitaxel

iRGD Modified Chemo‐immunotherapeutic Nanoparticles for Enhanced Immunotherapy against Glioblastoma

RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration.

In vitro and in vivo intracellular distribution and anti-glioblastoma effects of docetaxel-loaded nanoparticles functioned with IL-13 peptide.

DIPG-15. CONCURRENT GB-13 (IL13.E13K-PE4E) IMPROVES THE EFFICACY OF RADIATION THERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA

Antitumoral Cascade-Targeting Ligand for IL-6 Receptor-Mediated Gene Delivery to Glioma

Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma

Pinx1-Sirna/Mpeg-Pei-Spion Combined with Doxorubicin Enhances the Inhibition of Glioma Growth

Intelligent Nanoparticles With pH-Sensitive Co-Delivery of Temozolomide and siEGFR to Ameliorate Glioma Therapy

A multifunctional targeted nano-delivery system with radiosensitization and immune activation in glioblastoma

Enhanced Blood-Brain Barrier Penetration and Glioma Therapy Mediated by A New Peptide Modified Gene Delivery System

Mechanism of Polyethylene Glycol and Polyethylenimine Combined with Superparamagnetic Nanoparticles in Treating the Brain Glioma

Nanoparticles Functionalized with Pep-1 As Potential Glioma Targeting Delivery System Via Interleukin 13 Receptor Α2-Mediated Endocytosis.

Doxorubicin and indocyanine green loaded superparamagnetic iron oxide nanoparticles with PEGylated phospholipid coating for magnetic resonance with fluorescence imaging and chemotherapy of glioma